Literature DB >> 8106763

Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis.

F Dressler1, R Ackermann, A C Steere.   

Abstract

The antibody responses to the three genomic groups of Borrelia burgdorferi (B. burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii) were determined in 97 German patients with various manifestations of Lyme borreliosis. The geometric mean antibody titers in each patient group, determined by ELISA, were similar with each antigen preparation. By Western blotting, however, patients with meningopolyneuritis tended to respond to more spirochetal polypeptides of B. garinii, the group 2 strain, whereas those with arthritis recognized more antigens of B. afzelii, the group 3 strain (P < .03), as did those with acrodermatitis. Only 1 patient each with erythema migrans, arthritis, or acrodermatitis had weak reactivity with outer surface protein A (OspA), and none responded to OspB. It is concluded that differences among the three groups of B. burgdorferi may result in variations in the antibody response in European Lyme borreliosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8106763     DOI: 10.1093/infdis/169.2.313

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe.

Authors:  U Hauser; G Lehnert; B Wilske
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  A European multicenter study of immunoblotting in serodiagnosis of lyme borreliosis.

Authors:  J Robertson; E Guy; N Andrews; B Wilske; P Anda; M Granström; U Hauser; Y Moosmann; V Sambri; J Schellekens; G Stanek; J Gray
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  A twist on Lyme: the challenge of diagnosing European Lyme neuroborreliosis.

Authors:  Naila Makhani; Shaun K Morris; Andrea V Page; Jason Brophy; L Robbin Lindsay; Brenda L Banwell; Susan E Richardson
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

Review 4.  Host-pathogen interactions in the immunopathogenesis of Lyme disease.

Authors:  L T Hu; M S Klempner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

5.  Surface exposure and species specificity of an immunoreactive domain of a 66-kilodalton outer membrane protein (P66) of the Borrelia spp. that cause Lyme disease.

Authors:  J Bunikis; L Noppa; Y Ostberg; A G Barbour; S Bergström
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

6.  Seroprevalence of Borrelia burgdorferi in patients with Behçet's disease.

Authors:  Fatos Onen; Dilek Tuncer; Servet Akar; Merih Birlik; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2003-04-08       Impact factor: 2.631

7.  Identification of a new Borrelia species among small mammals in areas of northern Spain where Lyme disease is endemic.

Authors:  Horacio Gil; Marta Barral; Raquel Escudero; Ana L García-Pérez; Pedro Anda
Journal:  Appl Environ Microbiol       Date:  2005-03       Impact factor: 4.792

8.  Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection.

Authors:  B P Fung; G L McHugh; J M Leong; A C Steere
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Detection and molecular typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks and in different patient samples from southwest Germany.

Authors:  D Schaarschmidt; R Oehme; P Kimmig; R D Hesch; S Englisch
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

10.  Characterization of Finnish Borrelia burgdorferi sensu lato isolates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and with monoclonal antibodies.

Authors:  J Tuomi; L K Rantamäki; R Tanskanen; J Junttila
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.